Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Telomir Pharmaceuticals, Inc. (TELO)

Telomir Closes $5.6 Million Private Placement at $1.16 Per Share

Mixed Impact 3 of 5 financing Written later

Telomir Pharmaceuticals sold 4,843,300 shares of common stock at $1.16 per share in a private placement that closed on October 5, 2026, for approximately $5.6 million in gross proceeds before expenses. The company said it will use the proceeds mainly to support clinical development of Telomir-Zn, including its Phase 1/2 trial in advanced or metastatic triple-negative breast cancer, and for working capital. The new shares add to the existing share count and carry a placement agent fee and warrants, and the company must register the resale of the shares with the SEC.

Key points

  • 4,843,300 shares sold at $1.16 per share, a 5% discount to the 10-day VWAP on Nasdaq; closing on October 5, 2026
  • Approximately $5.6 million gross proceeds; existing shareholder John Paul DeJoria invested an additional $1.0 million
  • Placement agent Alexander Capital receives a cash fee of about $455,000 (9.0% of gross proceeds) and warrants for 387,464 shares at $1.16, expiring five years after issuance
  • Company must file a resale registration statement with the SEC within 30 days of the closing

The filing

CompanyTelomir Pharmaceuticals, Inc. (TELO)
Form8-K, current report
Filed with the SECOct 6, 2026, 8:00 AM ET
Accession number0001493152-26-045860

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.